Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Prospects and challenges of induced pluripotent stem cells as a source of hematopoietic stem cells.

van Bekkum DW, Mikkers HM.

Ann N Y Acad Sci. 2012 Aug;1266:179-88. doi: 10.1111/j.1749-6632.2012.06629.x. Review.

PMID:
22901269
2.

Promise and challenges of human iPSC-based hematologic disease modeling and treatment.

Ye Z, Chou BK, Cheng L.

Int J Hematol. 2012 Jun;95(6):601-9. doi: 10.1007/s12185-012-1095-9. Epub 2012 May 23. Review.

PMID:
22619021
3.

The challenges and promises of blood engineered from human pluripotent stem cells.

Dravid GG, Crooks GM.

Adv Drug Deliv Rev. 2011 Apr 30;63(4-5):331-41. doi: 10.1016/j.addr.2010.12.006. Epub 2011 Jan 11. Review.

PMID:
21232565
4.

Inability of human induced pluripotent stem cell-hematopoietic derivatives to downregulate microRNAs in vivo reveals a block in xenograft hematopoietic regeneration.

Risueño RM, Sachlos E, Lee JH, Lee JB, Hong SH, Szabo E, Bhatia M.

Stem Cells. 2012 Feb;30(2):131-9. doi: 10.1002/stem.1684.

5.
6.

Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors.

Finke J, Brugger W, Bertz H, Behringer D, Kunzmann R, Weber-Nordt RM, Kanz L, Mertelsmann R.

Bone Marrow Transplant. 1996 Dec;18(6):1081-6.

PMID:
8971376
7.

Development of patient-specific hematopoietic stem and progenitor cell grafts from pluripotent stem cells, in vitro.

Klump H, Teichweyde N, Meyer C, Horn PA.

Curr Mol Med. 2013 Jun;13(5):815-20. Review.

PMID:
23642062
8.

Allogeneic hematopoietic stem cell transplantation.

Kai S, Hara H.

Ther Apher Dial. 2003 Jun;7(3):285-91. Review.

PMID:
12924602
9.

Cryopreservation of hematopoietic stem/progenitor cells for therapeutic use.

Watt SM, Austin E, Armitage S.

Methods Mol Biol. 2007;368:237-59. Review.

PMID:
18080475
10.

Prospects and challenges of reprogrammed cells in hematology and oncology.

Groß B, Pittermann E, Reinhardt D, Cantz T, Klusmann JH.

Pediatr Hematol Oncol. 2012 Sep;29(6):507-28. doi: 10.3109/08880018.2012.708707. Epub 2012 Aug 2. Review.

PMID:
22857266
11.

[Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].

Michallet M, Dhedin N, Michallet AS.

Bull Cancer. 2001 Sep;88(9):908-26. Review. French.

12.
13.

Ex vivo expansion of hematopoietic stem cells: mission accomplished?

Takizawa H, Schanz U, Manz MG.

Swiss Med Wkly. 2011 Dec 29;141:w13316. doi: 10.4414/smw.2011.13316. Review.

14.

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe.

Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, Demirer T, Dini G, Einsele H, Gratwohl A, Madrigal A, Niederwieser D, Passweg J, Rocha V, Saccardi R, Schouten H, Schmitz N, Socie G, Sureda A, Apperley J; European Group for Blood and Marrow.

Bone Marrow Transplant. 2006 Mar;37(5):439-49.

PMID:
16444286
15.

Recent advances in hematopoietic stem cell transplantation and perspectives of RNAi applications.

Fløisand Y, Sioud M.

Methods Mol Biol. 2010;629:507-23. doi: 10.1007/978-1-60761-657-3_30. Review.

PMID:
20387168
16.
17.

How far are induced pluripotent stem cells from the clinic?

Li M, Chen M, Han W, Fu X.

Ageing Res Rev. 2010 Jul;9(3):257-64. doi: 10.1016/j.arr.2010.03.001. Epub 2010 Apr 1. Review.

PMID:
20362696
18.

Tu-mor(e) blood cells from human pluripotent stem cells.

Kaufman DS.

Blood. 2013 Feb 21;121(8):1245-6. doi: 10.1182/blood-2013-01-472563.

19.

Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.

Talmadge JE.

Int Immunopharmacol. 2003 Aug;3(8):1121-43. Review.

PMID:
12860168
20.

Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.

Resnick IB, Shapira MY, Slavin S.

Transpl Immunol. 2005 Aug;14(3-4):207-19. Epub 2005 Apr 26. Review.

PMID:
15982565

Supplemental Content

Support Center